A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.

Sustainability

Guided by our values, our employees work every day to make meaningful differences in healthcare. At the core of what we do is our most valuable resource - our people. Learn more about us.

Leadership
Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.  

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.  

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Working closely with our members, we're developing products and services to solve your most complex challenges.

Our most recent insights, articles and more, all in one place.  

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

The proactive, predictive and behind-the-scenes insights you need to stay ahead in healthcare delivered monthly to your inbox.

Statement on Emergency Use Approval for Moderna, Pfizer-BioNTech Omicron Booster Vaccines

By Soumi Saha, PharmD, JD, Senior Vice President, Government Affairs

Today’s FDA approval of the reformulated COVID-19 boosters that target the BA.4 and BA.5 Omicron sub variants can be a game changer for getting ahead of an evolving virus that continues to infect tens of thousands of Americans.

However, it’s critical that we don’t repeat some of the same problems that plagued COVID-19 vaccination efforts during the early pandemic response. As a national convener of hospital and non-acute vaccination sites across the nation, Premier recognized early on that a mass COVID-19 vaccination effort would be the biggest logistical challenge of the pandemic.

The COVID-19 fall booster campaign requires a cohesive national rollout and distribution plan with clear guidance from the Centers for Disease Control and Prevention (CDC) on vaccine allocation and eligibility for priority populations, including high-risk patients as well as those who have not yet received a booster.

Our nation also continues to lack information on the supplies needed to provide both COVID-19 and monkeypox treatment, all with the 2022 flu season on the horizon. It’s critical that the U.S. be aware of exactly where vaccine doses are being held and in the exact quantities – and it’s well past time we modernize the U.S. supply chain data infrastructure for greater data and transparency on supply availability and allocation methods. Additionally, vaccinators need detail on any ancillary kit that may accompany COVID-19 boosters and what products (i.e., needles syringes, nitrile exam gloves) may be included within. Casting further uncertainty over the rollout is the fact that government funding for the U.S. vaccine effort could run out as soon as January without additional support from Congress.

Overall, some public health experts are calling into question the speed of the booster authorization and rollout given unknowns around risk to vaccine effectiveness in humans. It’s vital that our public health vaccination approach is grounded in science – and we encourage the expeditious release of data and evidence from human trials that demonstrates booster efficacy. This is also key to helping overcome remaining hesitancy and further improve COVID-19 vaccination rates.

Login Register Change Registration